Out of the 475 participants randomized in the study, 451 (94.9%) completed the trial
Abstract Tirzepatide is the first dual long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes in adults, for reducing excess body weight and maintaining long-term weight reduction in adults with obesity or overweight and at least one weight-related comorbid condition, and for treating obstructive sleep apnea in adults with obesity
That finding surprised many researchers and requires careful interpretation
Nevertheless, the authors posited that local, tissue-level IGF-I production in targets such as skeletal muscle cells might still be modulated, even if overall IGF-I remains relatively stable
Understand the compounded-vs-approved distinction
Therefore, an optimal GSH/GSSG ratio must be maintained for physiological processes to occur